14.88

2.04% -0.31

After Hours: 14.97 0.09 +0.60%

Viridian Therapeutics Inc (VRDN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Viridian Therapeutics Inc stock is traded at $14.88, with a volume of 1.37M. It is down -2.04% in the last 24 hours and down -48.12% over the past month. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Previous Close:

$15.19

Open:

$15.21

24h Volume:

1.37M

Relative Volume:

0.67

Market Cap:

$1.52B

Revenue:

$70.85M

Net Income/Loss:

$-324.22M

P/E Ratio:

-3.9091

EPS:

-3.8065

Net Cash Flow:

$-277.36M

1W Performance:

+2.83%

1M Performance:

-48.12%

6M Performance:

-33.18%

1Y Performance:

+16.25%

1-Day Range:

$14.76

$15.34

1-Week Range:

$14.35

$15.58

52-Week Range:

$11.76

$34.29

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name

Viridian Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

617.272.4600

Address

221 CRESCENT STREET, WALTHAM

Employee

252

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

VRDN's Discussions on Twitter

Compare VRDN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRDN Viridian Therapeutics Inc	14.88	1.55B	70.85M	-324.22M	-277.36M	-3.8065
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Reiterated	Wedbush	Outperform
Dec-03-25	Initiated	William Blair	Outperform
Nov-24-25	Initiated	Truist	Buy
Aug-25-25	Resumed	Jefferies	Buy
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy
Jun-11-24	Initiated	Wolfe Research	Outperform
Jun-06-24	Initiated	Goldman	Buy
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jun-14-23	Initiated	BTIG Research	Buy
Jun-14-23	Resumed	Credit Suisse	Outperform
May-30-23	Initiated	RBC Capital Mkts	Outperform
Apr-17-23	Initiated	Wells Fargo	Overweight
Mar-30-23	Initiated	Stifel	Buy
Dec-19-22	Initiated	Cowen	Outperform
Dec-19-22	Initiated	Needham	Buy
Dec-16-22	Initiated	Credit Suisse	Outperform
Dec-01-22	Initiated	H.C. Wainwright	Buy
Jun-23-22	Initiated	B. Riley Securities	Buy
Nov-18-21	Initiated	SVB Leerink	Outperform
Oct-12-21	Initiated	Evercore ISI	Outperform
Jan-25-21	Initiated	Ladenburg Thalmann	Buy

View All

Viridian Therapeutics Inc Stock (VRDN) Latest News

Apr 14, 2026

Viridian Therapeutics (VRDN) price target decreased by 11.71% to 36.18 - MSN

Apr 14, 2026

Apr 13, 2026

Sectors Review: Is Viridian Therapeutics Inc undervalued by DCF analysisGap Down & Daily Technical Forecast Reports - baoquankhu1.vn

Apr 13, 2026

Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $24 - Moomoo

Apr 13, 2026

Portfolio Recap: Will Viridian Therapeutics Inc outperform its industry peersQuarterly Trade Report & Technical Confirmation Trade Alerts - baoquankhu1.vn

Apr 13, 2026

Avoiding Lag: Real-Time Signals in (VRDN) Movement - Stock Traders Daily

Apr 13, 2026

Apr 12, 2026

Viridian Therapeutics stock is tanking. Why the drop is linked to this Amgen study. - MSN

Apr 12, 2026

Why is Viridian Therapeutics stock sinking Monday? - MSN

Apr 12, 2026

Apr 11, 2026

Viridian Therapeutics (VRDN) Is Down 18.4% After Strong REVEAL-1 Elegrobart TED DataWhat's Changed - Sahm

Apr 11, 2026

Apr 10, 2026

Options Flow: Can Viridian Therapeutics Inc beat the S P 500Weekly Stock Report & Weekly High Momentum Picks - baoquankhu1.vn

Apr 10, 2026

Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $36 - Moomoo

Apr 10, 2026

Apr 09, 2026

Viridian Therapeutics (VRDN) soars 5.6%: Is further upside left in the stock? - MSN

Apr 09, 2026

Viridian Therapeutics price target lowered to $36 from $40 at Truist - Yahoo Finance

Apr 09, 2026

Apr 08, 2026

Why is Viridian Therapeutics stock falling Monday? - MSN

Apr 08, 2026

Stock Market Recap: Can Viridian Therapeutics Inc stock double in the next yearBreakout Watch & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn

Apr 08, 2026

Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN) - Seeking Alpha

Apr 08, 2026

VRDN: Wedbush Maintains Rating but Lowers Price Target | VRDN St - GuruFocus

Apr 08, 2026